Pharmacokinetics and erythropoietic response to human recombinant erythropoietin in healthy men

No abstract is available for this paper.

• Publication year

  1990

• Venue

  Clinical pharmacology and therapy

• Publication date

  1990-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/clpt.1990.76PMID 2188770
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Serum erythropoietin levels by radioimmunoassay in polycythaemia.

  2009cited by this paper
• The anemia of chronic renal failure: pathophysiology and effects of recombinant erythropoietin.

  1990cited by this paper
• Pharmacokinetics of intravenous recombinant human erythropoietin in patients with chronic renal failure

  1990cited by this paper
• Recombinant human erythropoietin treatment in pre-dialysis patients. A double-blind placebo-controlled trial.

  1989cited by this paper
• Increased preoperative collection of autologous blood with recombinant human erythropoietin therapy.

  1989cited by this paper
• The in vivo metabolism of recombinant human erythropoietin in the rat.

  1989cited by this paper
• The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin.

  1989cited by this paper
• Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney.

  1988cited by this paper
• Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridization.

  1988cited by this paper
• Correction of the anemia of end-stage renal disease with recombinant human erythropoietin.

  1987cited by this paper
• Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial.

  1987cited by this paper
• Renal erythropoietin: properties and production.

  1986cited by this paper
• Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis.

  1986cited by this paper
• Erythropoietin kinetics in normal and uremic sheep.

  1985cited by this paper
• Cloning and expression of the human erythropoietin gene.

  1985cited by this paper
• LAGRAN program for area and moments in pharmacokinetic analysis.

  1983cited by this paper
• Heparin kinetics determined by three assay methods

  1982cited by this paper
• Pharmacokinetics of heparin. I. Studies of dose dependence in rats.

  1979cited by this paper
• Pharmacokinetics of Heparin

  1975cited by this paper
• The liver as a source of extrarenal erythropoietin production.

  1972cited by this paper
• Effect of erythroid hyperplasia on the disappearance rate of erythropoietin in the dog.

  1968cited by this paper
• Studies on the Coumarin Anticoagulant Drugs : A Comparison of the Pharmacodynamics of Dicumarol and Warfarin in Man

  1964cited by this paper
• A Humoral Mechanism in Anoxic Erythrocytosis

  1948cited by this paper

• A full Target-Mediated Drug Disposition (TMDD) model to explain the changes in recombinant human erythropoietin (rhEpo) pharmacokinetics in patients with different bone marrow integrity following hematopoietic transplantation.

  2022cites this paper
• Comparison of Pharmacokinetic, Pharmacodynamic and Tolerability Profiles of CKD-11101, Darbepoetin Alfa (NESP®) Biosimilar, to Those of NESP® After a Single Subcutaneous or Intravenous Administration to Healthy Subjects

  2021cites this paper
• DDDT_A_303772 1735..1747

  2021cites this paper
• Pharmacokinetics during therapeutic hypothermia for neonatal hypoxic ischaemic encephalopathy: a literature review

  2020cites this paper
• Effect of compromised liver function and acute kidney injury on the pharmacokinetics of thymoquinone in a rat model

  2020cites this paper
• Pleiotropic effects of Erythropoietin. Influence of Erythropoietin on processes of mesenchymal stem cells differentiation

  2019influential citation
• A Mechanism‐Based Population Pharmacokinetics Model of Erythropoietin in Premature Infants and Healthy Adults Following Multiple Intravenous Doses

  2019cites this paper
• A comparative pharmacokinetic and pharmacodynamic study of two novel Cuban PEGylated rHuEPO versus MIRCERA® and ior®EPOCIM.

  2018cites this paper
• Comparison of the Pharmacokinetic–Pharmacodynamic Relationships of Two Darbepoetin Alfa Formulations in Healthy Male Volunteers

  2018cites this paper
• Clinical Evolution of a Pleiotropic Cytokine

  2017cites this paper
• Epoetin beta for the treatment of chemotherapy-induced anemia: an update

  2015cites this paper
• Probing protease sensitivity of recombinant human erythropoietin reveals α3–α4 inter‐helical loop as a stability determinant

  2015cites this paper
• Anemia e inflamación con la administración de estimulantes de la eritropoyesis y su resistencia en hemodiálisis

  2015cites this paper
• A combined model of human erythropoiesis and granulopoiesis under growth factor and chemotherapy treatment

  2014cites this paper
• Prediction of drug concentration-time profiles of therapeutic proteins in humans from animals

  2013cites this paper
• A Biomathematical Model of Human Erythropoiesis under Erythropoietin and Chemotherapy Administration

  2013cites this paper
• High-Dose Erythropoietin in Acute ST-Segment Elevation Myocardial Infarction: A Meta-Analysis of Randomized Controlled Trials

  2013cites this paper
• macaques induction, erythrocytosis, and fetal hemoglobin expression in rhesus HIF-prolyl hydroxylase inhibition results in endogenous erythropoietin

  2013cites this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Erythropoiesis-Stimulating Agents

  2013cites this paper
• Prophylaxis with erythropoietin versus placebo reduces acute kidney injury and neutrophil gelatinase-associated lipocalin in patients undergoing cardiac surgery: a randomized, double-blind controlled trial

  2013cites this paper
• A Review of its Pharmacological Properties and Clinical Use in the Management of Anaemia Associated with Chronic Renal Failure

  2012cites this paper
• Monomeric Fc Fusions

  2012cites this paper
• Population pharmacokinetic / pharmacodynamic analysis of erythropoiesis kinetics

  2012cites this paper
• Erythropoietin Stimulation and Other Blood Doping Methods

  2012cites this paper
• Epoetin Beta

  2012cites this paper
• Hematologic Aspects of Kidney Disease

  2012cites this paper
• THE EFFECT OF ALTITUDE EXPOSURE: VIA REBREATHING ON INTERVAL PERFORMANCE

  2011cites this paper
• Interspecies scaling and prediction of human clearance: comparison of small- and macro-molecule drugs

  2011influential citation
• Bleeding complications and transfusion in acute coronary syndrome

  2011cites this paper
• Prediction of human clearance of therapeutic proteins: simple allometric scaling method revisited

  2010cites this paper
• Pharmacokinetics of erythropoiesis-stimulating agents

  2009cites this paper
• Dynamics of target-mediated drug disposition.

  2009cites this paper
• Abuse of recombinant erythropoietins and blood products by athletes

  2009cites this paper
• Pharmacology, pharmacokinetics and safety of recombinant human erythropoietin preparations

  2008cites this paper
• A Phase I, Single and Fractionated, Ascending‐Dose Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of an Erythropoietin Mimetic Antibody Fusion Protein (CNTO 528) in Healthy Male Subjects

  2008cites this paper
• Iron and anemia in human biology: a review of mechanisms

  2008cites this paper
• Pharmacokinetics and pharmacodynamics of erythropoietin receptor in healthy volunteers

  2008cites this paper
• Effects of recombinant human erythropoietin on antiplatelet action of aspirin and clopidogrel in healthy subjects: results of a double-blind, placebo-controlled randomized trial.

  2007cites this paper
• Population Pharmacokinetics Meta-Analysis of Recombinant Human Erythropoietin in Healthy Subjects

  2007cites this paper
• Molecular, Biologic, and Pharmacokinetic Properties of Monoclonal Antibodies: Impact of These Parameters on Early Clinical Development

  2007cites this paper
• Change in Erythropoietin Pharmacokinetics Following Hematopoietic Transplantation

  2007influential citation
• Pharmacology of darbepoetin alfa.

  2007cites this paper
• Consideration of Endogenous Backgrounds

  2007cites this paper
• Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO)

  2007cites this paper
• HIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques.

  2007cites this paper
• Consideration of Endogenous Backgrounds in Pharmacokinetic Analyses

  2007cites this paper
• Epoetin beta in oncology: examining the current evidence.

  2006cites this paper
• Cellular Trafficking and Degradation of Erythropoietin and Novel Erythropoiesis Stimulating Protein (NESP)*

  2006cites this paper
• Analisi costo-efficacia di darbepoetina dopo switch da epoietina-beta nei pazienti in emodialisi: studio retrospettivo monocentrico italiano

  2006cites this paper
• Medikamentöse Therapie von Tumorschmerzen

  2006cites this paper
• Pulmonary administration of therapeutic proteins using an immunoglobulin transport pathway.

  2006cites this paper
• Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics.

  2006cites this paper
• The Absorption of Darbepoetin Alfa Occurs Predominantly via the Lymphatics Following Subcutaneous Administration to Sheep

  2006cites this paper
• IL‐6 and IL‐8 response to erythropoietin therapy in radical hysterectomy

  2005cites this paper
• Lymphatic Absorption Is the Primary Contributor to the Systemic Availability of Epoetin Alfa following Subcutaneous Administration to Sheep

  2005influential citation
• Delivery of an Erythropoietin-Fc Fusion Protein by Inhalation in Humans through an Immunoglobulin Transport Pathway

  2005cites this paper
• Untersuchungen zum Einfluss von Erythropoietin auf die myokardiale Funktion des ischämischen Schweineherzens

  2005cites this paper
• Optimizing anaemia management with subcutaneous administration of epoetin.

  2005cites this paper
• Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjects.

  2005cites this paper
• The Effects of Intermittent Hypoxic Exposure (IHE) on Haemorheology of Elite Middle Distance Runners

  2005cites this paper
• Recombinant human erythropoietin use in a critically ill Jehovah's witness after cardiac surgery.

  2005cites this paper
• Pharmacokinetic and Pharmacodynamic Modeling of Recombinant Human Erythropoietin After Single and Multiple Doses in Healthy Volunteers

  2004cites this paper
• Interspecies scaling of protein drugs: prediction of clearance from animals to humans.

  2004cites this paper
• Pharmacokinetic tracer kinetics analysis of changes in erythropoietin receptor population in phlebotomy‐induced anemia and bone marrow ablation

  2004cites this paper
• Erythropoietin production rate in phlebotomy‐induced acute anemia

  2004cites this paper
• Epoetin alfa. Clinical evolution of a pleiotropic cytokine.

  2004cites this paper
• Abuse of recombinant erythropoietins by athletes

  2003cites this paper
• Eritropoietina humana recombinante no esporte: uma revisao

  2003cites this paper
• Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in athletes. Blood sampling and doping control.

  2003cites this paper
• Clinical pharmacokinetic properties of rHuEPO: a review

  2003influential citation
• Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats

  2003cites this paper
• Proteins of the inter-α-inhibitor family : biosynthesis, plasma clearance and interaction with extracellular matrix components.

  2003cites this paper
• Recombinant human erythropoietin in sports: a review

  2003cites this paper
• A Differential Pharmacokinetic Analysis of the Erythropoietin Receptor Population in Newborn and Adult Sheep

  2003cites this paper
• Pharmacokinetics/Pharmacodynamics of Recombinant Human Erythropoietins in Doping Control

  2003cites this paper
• Pharmacokinetic-Pharmacodynamic Modelling of Recombinant Human Erythropoietin in Athletes

  2003cites this paper
• Anemia of Chronic Kidney Disease and its Management with Recombinant Human Erythropoietin and Darbepoetin Alfa

  2002cites this paper
• Detection of DNA-Recombinant Human Epoetin-Alfa as a Pharmacological Ergogenic Aid

  2002cites this paper
• Has the best route of administration for epoetin been established

  2002cites this paper
• Pharmacology, pharmacokinetics and safety of recombinant human erythropoietin (rhEPO)

  2002cites this paper
• The enigma of the metabolic fate of circulating erythropoietin (Epo) in view of the pharmacokinetics of the recombinant drugs rhEpo and NESP

  2002cites this paper
• Pharmacokinetics and Pharmacodynamics of Recombinant Human Erythropoietin in Rats

  2001cites this paper
• Recombinant human erythropoietin administration in cardiac surgery.

  2001cites this paper
• Identification of blood erythroid markers useful in revealing erythropoietin abuse in athletes.

  2001cites this paper
• Cessation of intensive treatment with recombinant human erythropoietin is followed by secondary anemia.

  2001cites this paper
• Changes in erythropoietin pharmacokinetics following busulfan-induced bone marrow ablation in sheep: evidence for bone marrow as a major erythropoietin elimination pathway.

  2001cites this paper
• Receptor-based model accounts for phlebotomy-induced changes in erythropoietin pharmacokinetics.

  2001cites this paper
• PHARMACOKINETICS OF SEVERAL SUBCUTANEOUS DOSES OF ERYTHROPOIETIN: POTENTIAL IMPLICATIONS FOR BLOOD TRANSFUSION

  2000cites this paper
• Simulated moderate altitude elevates serum erythropoietin but does not increase reticulocyte production in well-trained runners

  2000cites this paper
• Erythropoietin and anemia of cancer

  2000cites this paper
• Physiological and pharmacodynamic considerations for route of EPO administration.

  2000cites this paper
• Consideration of endogenous backgrounds in pharmacokinetic analyses: a simulation study

  2000cites this paper
• Clinical Applications of Recombinant Human Erythropoietin

  2000cites this paper
• A comparison of nonlinear pharmacokinetics of erythropoietin in sheep and humans

  1999cites this paper
• Biodegradable recombinant human erythropoietin loaded microspheres prepared from linear and star-branched block copolymers: influence of encapsulation technique and polymer composition on particle characteristics.

  1999cites this paper
• Simultaneous Improvement of Minimal-Change Nephrotic Syndrome and Anemia with Steroid Therapy

  1999cites this paper
• Recombinant erythropoietin in treatment of the premature newborn

  1998cites this paper
• Pharmacokinetics of erythropoietin in genetically anemic mice.

  1998cites this paper
• Human erythropoietin dimers with markedly enhanced in vivo activity.

  1998cites this paper
• Plasma disappearance of exogenous erythropoietin in mice under different experimental conditions

  1998cites this paper